Mentice AB (publ), Gothenburg – Mentice, a globally recognized leader in simulation solutions for image-guided interventional therapies, proudly announces that Ankyras®[1], a clinical decision-support application for patient-specific flow diverter planning, has received successful notification from ANVISA (Agência Nacional de Vigilância Sanitária), Brazil’s National Health Surveillance Agency.
‍

With this regulatory milestone, Mentice officially launches Ankyras® 6.0 for clinical use in Brazil, expanding access to personalized intracranial aneurysm treatment planning based on accurate device simulation and patient-specific anatomical modelling across Latin America.

‍

Current research suggests Brazil's intracranial aneurysm treatment market is projected to reach USD 86.5 million by 2030. Based on an estimated CAGR of 8.5%, this would place the market value at approximately USD 102 million by 2032. Additional insights from industry stakeholders indicate that Brazil already represents at least 60% of procedural volume across Latin America. These figures reinforce Brazil’s strategic position as the leading neurovascular market in the region and a key driver of intracranial aneurysm treatment growth in Latin America.[2]

Ankyras® is a neurovascular clinical decision-support application that provides detailed anatomical insights and enables the simulation of flow diverters (FD) to support precise device sizing and positioning assessment. The solution assists neuro-interventional teams with the planning, sizing, and selection of flow diverter devices for intracranial aneurysm treatment. By generating patient-specific vascular models from 3D rotational angiography (3DRA) or magnetic resonance angiography (MRA) images, Ankyras® provides a data-driven approach to optimizing treatment strategies.
‍

• For physicians, Ankyras® supports confident flow diverter sizing decisions, streamlines workflow through seamless DICOM integration, and reduces procedure planning time, allowing more focus on patient care.
• For medical device manufacturers, Ankyras® provides accurate, patient-specific device simulations, supporting physician engagement, accelerating technology adoption, and driving innovation in endovascular treatment planning.
  ‍

A key differentiator in Brazil is that physicians can bring their own cases to the VIST® simulation platform and rehearse treatment procedures in a virtual environment. This capability is already well adopted in Brazil through collaboration with SBNR (Brazilian Society of Neuroradiology) and is part of Mentice's broader commitment to advance virtual rehearsal and patient-specific simulation in neurointervention.
‍
Following a successful European launch, Ankyras® now complies with Brazilian regulatory and clinical standards, enabling seamless integration into clinical workflows and industry collaboration across Brazil and Latin America.
‍

Key Features of Ankyras® 6.0:

• Seamless DICOM Integration: Directly transfers imaging data from angiography systems to Ankyras®, eliminating manual data handling and streamlining clinical workflows.
• Accurate Device Simulation: Predicts flow diverter device foreshortening and final placement with a simulation accuracy averaging 94%.
• Broad Device Compatibility: Supports a wide range of flow diverters from multiple manufacturers, enhancing flexibility.
• Multi-Platform Accessibility: Available via web-based platforms, desktop applications, and mobile apps to support planning across multiple clinical environments.
  ‍
  

"Bringing Ankyras® to Brazil with ANVISA represents a major achievement for Mentice and a significant advancement for neurointerventional practice in Latin America," said Laura Obradó, Project Manager Ankyras at Mentice. "We are excited to provide Brazilian physicians with a validated, patient-specific solution that enhances precision, efficiency, and clinical outcomes in the treatment of intracranial aneurysms. By making streamlined, patient-specific aneurysm treatment planning more widely available, we are supporting Interventional Neuroradiologists make faster, more informed decisions, and now even rehearse their cases in the virtual environment using VIST® to ultimately improve patient outcomes."

Mentice will collaborate with leading Brazilian institutions to provide training, onboarding, and clinical support, ensuring a smooth and impactful introduction of Ankyras to the region.

Availability
Following successful ANVISA notification, Ankyras® 6.0 is now available for clinical use in Brazil. The platform is accessible via cloud-based services, local desktop installations, and mobile devices via the App Store and Google Play.

For more information on Ankyras® availability in Brazil, clinical integration, or to book a demo, visit here.

---
Sources:
[1] https://www.mentice.com/ankyras  
[2] Intracranial Aneurysm Market Size | Industry Report, 2030

---
For media inquiries, clinical demos, or partnership opportunities, please contact:
Martina Andreasson, Global Product Manager for Neurovascular and Ankyras at Mentice
E-post: martina.andreasson@mentice.com
Mobile: +46 733 660 247

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB